Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinopathy of Prematurity Clear all
Completed No phase listed Observational

Telemedicine Approaches to Evaluating Acute-phase ROP

NCT01264276
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
32 Weeks to 40 Weeks
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
11
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Sep 23, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

NCT02375971
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Ranibizumab, Laser therapy
Drug · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Loma Linda, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 23, 2026, 9:15 PM EDT
Completed No phase listed Observational

Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity

NCT01780155
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Retinopathy of Prematurity, Prematurity, Pulmonary Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 23, 2026, 9:15 PM EDT
Terminated No phase listed Observational

Telemedicine Approaches to Evaluating Acute-Phase ROP eROP Implementation Project

NCT02257307
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
RetCam retinal imaging used for routine care
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
32 Weeks to 40 Weeks
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Baltimore, Maryland • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 23, 2026, 9:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Time Outside Target Oxygen Saturation Range in Preterm Infants and Long Term Outcomes and Preterm Infants

NCT00845624
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
1 Day to 12 Months
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Sep 23, 2026, 9:15 PM EDT
Completed Phase 2Phase 3 Interventional

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity

NCT01203436
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Blindness
Interventions
Supplemental Oxygen Management, Conventional Oxygen Management
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
9
States / cities
Palo Alto, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 23, 2026, 9:15 PM EDT
Terminated Phase 3 Interventional Results available

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

NCT04634604
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab, Laser
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 9:15 PM EDT
Terminated Not applicable Interventional

Use of Sucrose to Relieve Pain During Eye Exams in Infants

NCT00161694
View directory record Official record
Conditions
Apnea of Prematurity, Retinopathy of Prematurity, Pain
Interventions
sucrose solution
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
5 Weeks and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Sep 23, 2026, 9:15 PM EDT
Recruiting No phase listed Observational

Imaging Retinal Vasculature in Infant Eyes

NCT05558059
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Handheld Optical Coherence Tomography with OCT Angiography
Device
Lead sponsor
Duke University
Other
Eligibility
Up to 2 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 23, 2026, 9:15 PM EDT
Terminated No phase listed Observational

A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity

NCT01335113
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 23, 2026, 9:15 PM EDT
No Longer Available No phase listed Expanded access

Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

NCT00870636
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab (Avastin)
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
30 Weeks and older
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Sep 23, 2026, 9:15 PM EDT
Recruiting No phase listed Observational

Point-of-Care Ophthalmic Diagnostic Imaging of Retinopathy of Prematurity

NCT06612541
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP), ROP Examination
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
24 Weeks to 34 Weeks
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 23, 2026, 9:15 PM EDT
Active, not recruiting No phase listed Observational

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

NCT04515524
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
11 Months to 5 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 23, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)

NCT02344225
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Caffeine citrate, Ibuprofen, Ketorolac
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
Up to 28 Weeks
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 23, 2026, 9:15 PM EDT
Completed Phase 2 Interventional

Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants

NCT00349726
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol higher volume, Placebo lower volume, Placebo higher volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
3 Days to 6 Days
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 23, 2026, 9:15 PM EDT
Terminated Not applicable Interventional Results available

Proparacaine and Mydriatic Eye Drops

NCT01266824
View directory record Official record
Conditions
Pain, Retinopathy of Prematurity
Interventions
Proparacaine Hydrochloride Ophthalmic Solution
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Sep 23, 2026, 9:15 PM EDT
Not listed Phase 2 Interventional Results available

Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity

NCT00622726
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab, Conventional Laser for ROP
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
4 Weeks to 22 Weeks
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
15
States / cities
Pasadena, California • Denver, Colorado • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 23, 2026, 9:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Registry for Severe ROP and Treatment on Visual Outcomes

NCT01559571
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Not listed
Lead sponsor
Pediatrix
Other
Eligibility
Up to 7 Days
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
2
States / cities
South Bend, Indiana • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 23, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Rainbow Extension Study

NCT02640664
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
Ranibizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 23, 2026, 9:15 PM EDT
Recruiting Phase 1 Interventional

Safety, PK and PD of FLQ-101 in Premature Neonates

NCT07093255
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
FLQ-101
Drug
Lead sponsor
FELIQS INC.
Industry
Eligibility
4 Days to 5 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 23, 2026, 9:15 PM EDT
Completed No phase listed Observational

ROP Check Database Premature Infant Outcomes

NCT07312669
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
Not listed
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
Not listed
Enrollment
7,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 23, 2026, 9:15 PM EDT
Terminated Phase 1 Interventional

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity

NCT00702819
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab
Drug
Lead sponsor
Vision Research Foundation
Other
Eligibility
30 Weeks to 36 Weeks
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • Menlo Park, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Sep 23, 2026, 9:15 PM EDT
Not listed Not applicable Interventional

Eye Shields for Infants After Dilated Exam

NCT04519060
View directory record Official record
Conditions
Infant, Newborn, Disease, Pain, Retinopathy of Prematurity, Eye Diseases
Interventions
phototherapy eye shield
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 1 Year
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 23, 2026, 9:15 PM EDT
Terminated Phase 3 Interventional Results available

Inositol to Reduce Retinopathy of Prematurity

NCT01954082
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
myo-Inositol 5% Injection, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 23, 2026, 9:15 PM EDT